Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 17,643 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Open Label Clear all
Completed Phase 2 Interventional Results available

Study Of Ispinesib In Subjects With Breast Cancer

NCT00089973
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Ispinesib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Jacksonville, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 2Phase 3 Interventional

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

NCT01741194
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AC-1204, Placebo
Drug
Lead sponsor
Cerecin
Industry
Eligibility
66 Years to 90 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects on Bioavailability of MDMA in Healthy Volunteers

NCT05147402
View directory record Official record
Conditions
Pharmacokinetics
Interventions
midomafetamine
Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

NCT02933502
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
DSXS topical product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

NCT02271945
View directory record Official record
Conditions
Relapsed/Refractory Aggressive B-cell Lymphomas
Interventions
MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Not applicable Interventional

Vestibular Innovation in Pain

NCT06559839
View directory record Official record
Conditions
Pain, Fatigue, Quality of Life
Interventions
Vestibulocortical Stimulation
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers

NCT01875939
View directory record Official record
Conditions
Effect of Food
Interventions
Oral WCK2349, IV WCK771
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 23, 2026, 9:11 PM EDT
Withdrawn Phase 2 Interventional

Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

NCT04174677
View directory record Official record
Conditions
Highly Sensitized Patients on Waiting List for Kidney Transplantation
Interventions
Inebilizumab, VIB4920, Inebilzumab+VIB4920
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
San Diego, California • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 23, 2026, 9:11 PM EDT
Terminated Phase 2 Interventional

Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice

NCT00291057
View directory record Official record
Conditions
Lice Infestations
Interventions
MALG
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months to 24 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Oct 23, 2026, 9:11 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT05355701
View directory record Official record
Conditions
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions
PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects

NCT02073812
View directory record Official record
Conditions
Healthy Subjects
Interventions
RPX7009 and RPX2014
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 23, 2026, 9:11 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

NCT03851081
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive, Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells, Lymphoblasts 20 Percent or More of Peripheral Blood White Cells, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions
Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 23, 2026, 9:11 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

NCT03434119
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
85
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition

NCT01888328
View directory record Official record
Conditions
Healthy
Interventions
Isotretinoin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Quadrangle Drive, Chapel Hill,, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

NCT00543569
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Alefacept, tacrolimus, basiliximab, mycophenolate mofetil, Corticosteroids
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
38
States / cities
Loma Linda, California • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

NCT03931941
View directory record Official record
Conditions
Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions
RBX2660
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

NCT00039741
View directory record Official record
Conditions
HIV Infections
Interventions
NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
29
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 23, 2026, 9:11 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

NCT06660654
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumors
Interventions
Raludotatug deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Marietta, Georgia • Ann Arbor, Michigan • East Brunswick, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 3 Interventional

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

NCT06901505
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
Erythropoiesis-Stimulating Agent (ESA), Vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
18
States / cities
Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 3 Interventional Results available

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

NCT02610231
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Istradefylline 20 mg or 40 mg
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
30 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 23, 2026, 9:11 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

NCT06188702
View directory record Official record
Conditions
MTAP-deleted Solid Tumors
Interventions
S095035, TNG462
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Lake Mary, Florida • Indianapolis, Indiana • Maumee, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 4 Interventional

Enstilar in Combination With Biologic Agents

NCT03080545
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies

NCT04162795
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Loratadine (Claritin, BAY76-2211)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 23, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

NCT00088595
View directory record Official record
Conditions
Carcinoid Tumors
Interventions
Pasireotide (SOM230)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 23, 2026, 9:11 PM EDT